Neumann Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Neumann Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$423K	Sell	2,226 -12	-0.5%	-$2.06K	0.28%	46
2026 Q1	$378K	Hold	2,238	–	–	0.11%	87
2025 Q4	$378K	Hold	2,238	–	–	0.11%	88
2025 Q3	$323K	Hold	2,238	–	–	0.09%	92
2025 Q2	$283K	Hold	2,238	–	–	0.09%	92
2025 Q1	$286K	Hold	2,238	–	–	0.1%	93
2024 Q4	$296K	Hold	2,238	–	–	0.1%	92
2024 Q3	$326K	Hold	2,238	–	–	0.11%	91
2024 Q2	$307K	Hold	2,238	–	–	0.11%	88
2024 Q1	$307K	Hold	2,238	–	–	0.11%	85
2023 Q4	$304K	Hold	2,238	–	–	0.12%	86
2023 Q3	$274K	Buy	2,238 +180	+9%	+$22.9K	0.12%	83
2023 Q2	$261K	Hold	2,058	–	–	0.11%	86
2023 Q1	$266K	Hold	2,058	–	–	0.12%	86
2022 Q4	$270K	Hold	2,058	–	–	0.13%	80
2022 Q3	$241K	Hold	2,058	–	–	0.12%	82
2022 Q2	$242K	Hold	2,058	–	–	0.12%	76
2022 Q1	$268K	Sell	2,058 -800	-28%	-$104K	0.11%	82
2021 Q4	$436K	Sell	2,858 -800	-22%	-$124K	0.18%	67
2021 Q3	$591K	Hold	3,658	–	–	0.27%	62
2021 Q2	$599K	Hold	3,658	–	–	0.27%	60
2021 Q1	$551K	Hold	3,658	–	–	0.26%	60
2020 Q4	$554K	Hold	3,658	–	–	0.28%	58
2020 Q3	$495K	Hold	3,658	–	–	0.28%	58
2020 Q2	$500K	Hold	3,658	–	–	0.31%	59
2020 Q1	$394K	Buy	3,658 +956	+35%	+$110K	0.29%	59
2019 Q4	$326K	Sell	2,702 -956	-26%	-$107K	0.19%	65
2019 Q3	$364K	Hold	3,658	–	–	0.23%	64
2019 Q2	$399K	Sell	3,658 -100	-3%	-$10.6K	0.25%	63
2019 Q1	$420K	Hold	3,758	–	–	0.27%	63
2018 Q4	$362K	Sell	3,758 -150	-4%	-$15.9K	0.27%	62
2018 Q3	$477K	Hold	3,908	–	–	0.28%	60
2018 Q2	$429K	Hold	3,908	–	–	0.27%	60
2018 Q1	$417K	Sell	3,908 -570	-13%	-$63.2K	0.27%	60
2017 Q4	$478K	Sell	4,478 -1	-0%	-$107	0.29%	65
2017 Q3	$498K	Hold	4,479	–	–	0.31%	65
2017 Q2	$463K	Hold	4,479	–	–	0.3%	65
2017 Q1	$438K	Sell	4,479 -3,630	-45%	-$348K	0.28%	66
2016 Q4	$717K	Hold	8,109	–	–	0.46%	54
2016 Q3	$782K	Hold	8,109	–	–	0.52%	50
2016 Q2	$696K	Hold	8,109	–	–	0.46%	51
2016 Q1	$705K	Hold	8,109	–	–	0.46%	53
2015 Q4	$915K	Hold	8,109	–	–	0.64%	48
2015 Q3	$820K	Hold	8,109	–	–	0.58%	51
2015 Q2	$997K	Hold	8,109	–	–	0.64%	50
2015 Q1	$928K	Hold	8,109	–	–	0.59%	53
2014 Q4	$820K	Buy	+8,109	New	+$788K	0.53%	54

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Neumann Capital Management's IBB Position: Q2 2026 in Review

Neumann Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 0.54% in Q2 2026, selling an estimated $2.06K and leaving 2,226 shares worth $423K. The position accounts for 0.28% of the portfolio, ranked #46.

Neumann Capital Management first reported a position in IBB in Q4 2014 and has held it in 47 quarters since. The position peaked at $997K in Q2 2015. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Neumann Capital Management held 2,226 shares of iShares Biotechnology ETF worth $423K as of Q2 2026.
Neumann Capital Management sold 12 iShares Biotechnology ETF shares in Q2 2026, an estimated $2.06K.
iShares Biotechnology ETF made up 0.28% of Neumann Capital Management's portfolio in Q2 2026, its #46 holding.
Neumann Capital Management first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 47 quarters since.
Neumann Capital Management's iShares Biotechnology ETF position peaked at $997K in Q2 2015.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Neumann Capital Management's 13F filing for Q2 2026, filed 13 Jul 2026.